A pivotal, single, global, Phase 3 study evaluating the 240 mg dose of alvelestat versus placebo in patients with alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2024 According to a Mereo Biopharma media release, following the FDA feedback on the detailed Phase 3 package, including the study protocol and the initial validation work on SGRQ in AATD, the Company continues to expect that alvelestat will be Phase 3 ready around the end of 2024. Company remains in discussions with several potential partners regarding the development and commercialization of alvelestat for AATD.
13 Aug 2024 According to a Mereo Biopharma media release, At the end of Q2, Mereo submitted the initial validation work for SGRQ in AATD and the detailed Phase 3 package including the study protocol to the FDA.
27 Mar 2024 According to a Mereo Biopharma media release, The company aims to initiate the Phase 3 study with a partner around the end of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com